Acrivon Therapeutics Inc
ACRV
Get informed when a big investor buys or sells
+ FollowMarket Cap$50.49M
Close$
$1.01
33.3% downside
Current Fair Value
33.3% downsideOvervalued by 33.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $50.49 Million |
|---|---|
| Enterprise Value | $18.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.02 |
| Beta | 2.02 |
| Outstanding Shares | 38,724,803 |
Return
| Return on Equity | -80.90% |
|---|---|
| Return on Assets | -71.65% |
| Return on Invested Capital | -90.34% |
Valuation & Multiples
| P/E Ratio | -0.8 |
|---|---|
| PEG | 24.74 |
| Price to Sales | - |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.22 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$277,167
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$386,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.16%▼ 6.10% |
|---|---|
| Total Invested | $22.57M▼ 49.68% |
| Investors Holding | 43▼ 5.00% |
ESG Score
No data